|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MUC5AC |
Gene summary for MUC5AC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MUC5AC | Gene ID | 4586 |
| Gene name | mucin 5AC, oligomeric mucus/gel-forming | |
| Gene Alias | MUC5 | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | P98088 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4586 | MUC5AC | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.13e-19 | 1.37e+00 | -0.1808 |
| 4586 | MUC5AC | HTA11_411_2000001011 | Human | Colorectum | SER | 1.35e-12 | 1.44e+00 | -0.2602 |
| 4586 | MUC5AC | Pat01-B | Human | Stomach | GC | 1.70e-18 | -8.56e-01 | 0.5754 |
| 4586 | MUC5AC | Pat02-B | Human | Stomach | GC | 1.84e-06 | 6.37e-02 | 0.0368 |
| 4586 | MUC5AC | Pat03-B | Human | Stomach | GC | 7.52e-12 | -7.36e-01 | 0.3693 |
| 4586 | MUC5AC | Pat04-B | Human | Stomach | GC | 2.42e-02 | 1.37e-01 | -0.1483 |
| 4586 | MUC5AC | Pat06-B | Human | Stomach | GC | 2.47e-12 | -1.01e-01 | -0.1961 |
| 4586 | MUC5AC | Pat07-B | Human | Stomach | GC | 2.28e-06 | -1.06e+00 | 0.0935 |
| 4586 | MUC5AC | Pat08-B | Human | Stomach | GC | 1.69e-02 | -6.86e-01 | 0.0182 |
| 4586 | MUC5AC | Pat09-B | Human | Stomach | GC | 3.66e-08 | -5.37e-01 | -0.0359 |
| 4586 | MUC5AC | Pat11-B | Human | Stomach | GC | 1.60e-10 | 3.15e-01 | -0.182 |
| 4586 | MUC5AC | Pat12-B | Human | Stomach | GC | 8.47e-04 | -1.81e-01 | 0.0325 |
| 4586 | MUC5AC | Pat15-B | Human | Stomach | GC | 5.88e-05 | 2.99e-02 | -0.0778 |
| 4586 | MUC5AC | Pat16-B | Human | Stomach | GC | 3.57e-13 | -6.92e-01 | 0.1918 |
| 4586 | MUC5AC | Pat18-B | Human | Stomach | GC | 6.42e-06 | 4.30e-01 | -0.0432 |
| 4586 | MUC5AC | Pat22-B | Human | Stomach | GC | 9.39e-03 | 2.36e-01 | -0.1042 |
| 4586 | MUC5AC | Pat24-B | Human | Stomach | GC | 3.58e-03 | 6.05e-02 | -0.1184 |
| 4586 | MUC5AC | Pat25-A | Human | Stomach | CAG with IM | 1.47e-10 | -3.99e-02 | -0.1648 |
| 4586 | MUC5AC | Pat26-A | Human | Stomach | CSG | 9.50e-20 | -5.05e-02 | -0.2402 |
| 4586 | MUC5AC | Pat28-A | Human | Stomach | CSG | 8.27e-12 | -2.06e-01 | -0.2594 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00480171 | Colorectum | SER | inositol lipid-mediated signaling | 42/2897 | 182/18723 | 4.36e-03 | 3.49e-02 | 42 |
| GO:00480151 | Colorectum | SER | phosphatidylinositol-mediated signaling | 41/2897 | 178/18723 | 4.97e-03 | 3.86e-02 | 41 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04657 | Stomach | GC | IL-17 signaling pathway | 18/708 | 94/8465 | 6.78e-04 | 5.42e-03 | 3.82e-03 | 18 |
| hsa046571 | Stomach | GC | IL-17 signaling pathway | 18/708 | 94/8465 | 6.78e-04 | 5.42e-03 | 3.82e-03 | 18 |
| hsa046572 | Stomach | CAG with IM | IL-17 signaling pathway | 18/640 | 94/8465 | 1.99e-04 | 1.86e-03 | 1.30e-03 | 18 |
| hsa046573 | Stomach | CAG with IM | IL-17 signaling pathway | 18/640 | 94/8465 | 1.99e-04 | 1.86e-03 | 1.30e-03 | 18 |
| hsa046574 | Stomach | CSG | IL-17 signaling pathway | 18/633 | 94/8465 | 1.73e-04 | 1.61e-03 | 1.16e-03 | 18 |
| hsa046575 | Stomach | CSG | IL-17 signaling pathway | 18/633 | 94/8465 | 1.73e-04 | 1.61e-03 | 1.16e-03 | 18 |
| hsa046576 | Stomach | CAG | IL-17 signaling pathway | 15/368 | 94/8465 | 1.13e-05 | 1.49e-04 | 1.19e-04 | 15 |
| hsa046577 | Stomach | CAG | IL-17 signaling pathway | 15/368 | 94/8465 | 1.13e-05 | 1.49e-04 | 1.19e-04 | 15 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MUC5AC | SNV | Missense_Mutation | novel | c.9491N>G | p.Thr3164Arg | p.T3164R | P98088 | protein_coding | tolerated(0.18) | unknown(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.10287N>A | p.Ser3429Arg | p.S3429R | P98088 | protein_coding | tolerated(0.05) | unknown(0) | TCGA-A8-A08X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD |
| MUC5AC | SNV | Missense_Mutation | novel | c.1705N>A | p.Gly569Ser | p.G569S | P98088 | protein_coding | deleterious(0) | unknown(0) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| MUC5AC | SNV | Missense_Mutation | novel | c.9032N>A | p.Ser3011Asn | p.S3011N | P98088 | protein_coding | tolerated_low_confidence(0.33) | unknown(0) | TCGA-AC-A4ZE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.6406N>T | p.His2136Tyr | p.H2136Y | P98088 | protein_coding | tolerated(0.71) | unknown(0) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.8537N>G | p.Ser2846Cys | p.S2846C | P98088 | protein_coding | deleterious_low_confidence(0.02) | unknown(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.9449N>G | p.Ser3150Cys | p.S3150C | P98088 | protein_coding | tolerated(0.09) | unknown(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.9395N>T | p.Thr3132Ile | p.T3132I | P98088 | protein_coding | tolerated(0.17) | unknown(0) | TCGA-E2-A570-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.7043N>T | p.Pro2348Leu | p.P2348L | P98088 | protein_coding | deleterious(0.02) | unknown(0) | TCGA-E2-A572-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| MUC5AC | SNV | Missense_Mutation | novel | c.13705C>G | p.Pro4569Ala | p.P4569A | P98088 | protein_coding | tolerated(0.14) | unknown(0) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4586 | MUC5AC | DRUGGABLE GENOME | CHEMBL1743013 | ENSITUXIMAB | ||
| 4586 | MUC5AC | DRUGGABLE GENOME | KLS-0611 | |||
| 4586 | MUC5AC | DRUGGABLE GENOME | GLUCOCORTICOID | 11411550 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |